Cancers: Innovative Technologies Changing Cancer Treatment
Cancers: Innovative Technologies Changing Cancer Treatment
Cancers: Innovative Technologies Changing Cancer Treatment
Conference Report
Innovative Technologies Changing Cancer Treatment
Sara Charmsaz 1,† ID , Maria Prencipe 2,† , Maeve Kiely 3,† , Graham P. Pidgeon 4 and
Denis M. Collins 5, *
1 RCSI Surgery, Royal College of Surgeons in Ireland, 31A York Street, Dublin 2, Ireland; saracharmsaz@rcsi.ie
2 School of Biomolecular and Biomedical Research, UCD Conway Institute of Biomolecular and Biomedical
Research, University College Dublin, Belfield, Dublin 4, Ireland; maria.prencipe@ucd.ie
3 Graduate Entry Medical School, University of Limerick, Limerick, Ireland; maeve.kiely@ul.ie
4 Trinity Translational Medicine Institute (TTMI), St. James’s Hospital and Trinity College Dublin,
Dublin 2, Ireland; PIDGEONG@tcd.ie
5 Cancer Biotherapeutics, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin,
Dublin 9, Ireland
* Correspondence: denis.collins@dcu.ie; Tel.: +353-1-700-5647
† These authors contributed equally to this work.
Received: 17 May 2018; Accepted: 14 June 2018; Published: 19 June 2018
Abstract: Conventional therapies for cancer such as chemotherapy and radiotherapy remain a
mainstay in treatment, but in many cases a targeted approach is lacking, and patients can be
vulnerable to drug resistance. In recent years, novel concepts have been emerging to improve
the traditional therapeutic options in cancers with poor survival outcomes. New therapeutic
strategies involving areas like energy metabolism and extracellular vesicles along with advances
in immunotherapy and nanotechnology are driving the next generation of cancer treatments.
The development of fields such as theranostics in nanomedicine is also opening new doors for targeted
drug delivery and nano-imaging. Here we discuss the use of innovative technologies presented at
the Irish Association for Cancer Research (IACR) Annual Meeting, highlighting examples of where
new approaches may lead to promising new treatment options for a range of cancer types.
1. Introduction
The transformative impact of technological advances on cancer research featured prominently at
the 54th annual meeting of the Irish Association for Cancer Research (IACR). Translational research is
advancing its enormous potential at breakneck speed, as mature applied technologies meet with the
innovations of multi-disciplinary research groups. High-throughput omics studies (e.g., genomics,
proteomics, metabolomics, transcriptomics) utilize new technologies to generate enormous datasets
that are being mined with ever-more specificity and value [1]. The potential of routine diagnostic
technologies, including magnetic resonance imaging (MRI), computed tomography (CT), positron
emission tomography (PET) imaging, and immunohistochemical analysis of tissues is being fully
understood through the development of the fields of radiomics and pathomics [2,3]. Nanomedicine
is harnessing the power of nanotechnology to improve drug delivery, pharmaceutical properties,
imaging, and diagnosis, establishing the area of theranostics [4,5]. The ability to isolate, characterise,
and functionally phenotype nanometer-scale extracellular vesicles is opening up new possibilities
for the therapeutic and diagnostic use of these intercellular RNA, DNA, and protein carriers [6].
Tissue processing and high-throughput fluorimetry underpins novel tools like BH3 profiling to
predict cellular response to chemotherapeutic agents [7]. The concept of sensitizing cancer cells
to radiotherapy has been investigated for close to 50 years but new advances are seeing more effective
small molecule (oxygen/oxygen mimics), macromolecule (miRNA, siRNA, peptide), and engineered
nanomaterial-based radiosensitisers emerge [8]. Here we discuss novel studies presented at the 2018
IACR Annual Meeting, which showcased these cutting-edge technologies and their applications in the
cancer research arena.
that affect processes in mitochondria linked to key features of the neoplastic phenotype. Damage to
the mitochondria is at the crossroad between normal metabolism and the regulation of cell death,
and represents an important direction for the development of new therapies. Those targets that can
regulate mitochondria function and metabolism and simultaneously increase sensitivity to induction
of apoptosis may be the most effective anti-cancer agents.
Prof. O’Sullivan’s group (Trinity Translational Medicine Institute, Trinity College Dublin) has
a particular focus on understanding the role of the mitochondria and energy metabolism in models
of oesophageal cancer (OAC) radiation resistance. In Ireland, incidence of OAC has increased
by 48% over the past 15 years and the overall cure rate is less than 20% [18]. Consequently, a
multi-modal approach to treating this disease involves neoadjuvant treatment (treatment prior to
surgery) with either chemotherapy alone or combination chemoradiotherapy (neo-CRT) for locally
advanced tumours [24,25]. Unfortunately, only ~30% of patients show a beneficial response with ~70%
of patients receiving a toxic treatment with no benefit. These patients also experience a delay to surgery
which may significantly affect overall patient survival.
Using an isogenic model of OAC radioresistance, Prof. O’Sullivan’s group has shown
that radioresistance is associated with altered mitochondria structure and size. The levels of
random mitochondrial mutations and altered metabolic profiles demonstrated metabolic plasticity,
efficiently switching between glycolysis and oxidative phosphorylation energy metabolism pathways
accompanied by enhanced clonogenic survival [26]. In vivo using patient samples, energy metabolism
as measured by the levels of ATP synthase F1 subunit beta (ATP5B) can significantly segregate
responders and non-responders to neoadjuvant chemoradiation treatment [26].
Through a gastrointestinal drug discovery programme, Prof. O’Sullivan’s group has identified
and patented a novel radiosensitiser with dual anti-metabolic and anti-angiogenic activity. Using
an in vivo zebrafish model and human ex vivo OAC explant models, they have shown this small
molecule inhibitor can significantly reduce both metabolic and anti-angiogenic activity in real time
and in parallel with increasing radiosensitivity in an isogenic model of radioresistance. Importantly,
the action of this novel small molecule is also effective under hypoxic conditions. Prof. O’Sullivan’s
group is building further pre-clinical data on the use of this novel radiosensitiser in the neoadjuvant
treatment setting for gastrointestinal malignancies.
in addition to regulating the stability of certain miRNAs and mRNAs through a process known as
regulated IRE1-dependent decay (RIDD). Somatic mutations in the IRE1 gene have been identified
in GBM and other forms of cancer. Taking advantage of the specific signalling outputs of the RNase
domain of IRE1 engaged by distinct GBM-related mutations, they defined specific expression signatures
that were then investigated in the context of human GBM transcriptomes. This approach allowed them
to demonstrate the antagonistic roles of XBP1 mRNA splicing and RIDD on tumour outcomes. As part
of this response, they demonstrated that the IRE1/XBP1 axis ensures the secretion of pro-inflammatory
chemokines by the tumour cells, thereby promoting the recruitment of tumour-associated macrophages,
microglial cells and to some extent, neutrophils. This was demonstrated with cell lines, primary GBM
lines, and using in vivo GBM orthotopic mouse models and patient tumour samples [31].
This study provides the first demonstration of a dual role of IRE1 downstream signalling in cancer
and opens a new therapeutic window to abrogate tumour progression. This study also indicates that
ER stress as well as UPR and IRE1 signalling might represent appealing targets for the development of
therapeutics that could in turn be used either alone or as adjuvant to the current treatments.
Author Contributions: Writing—Original Draft Preparation, M.P., S.C., M.K. and D.M.C.; Writing—Review and
Editing, M.P., S.C., M.K. and D.M.C.; Project Administration, M.P., S.C., M.K., D.M.C., G.P.P.
Funding: This work received no external funding.
Acknowledgments: We would like to thank all speakers at the IACR meeting with apologies to those speakers
whose work could not be included. Thank you to the speakers whose work is included and who contributed to
the writing of this report, we are most grateful (Table A1). The IACR annual meeting is organized and run by the
IACR council. We would like to extend thanks to all council members for their efforts in planning such a valuable
and successful international conference. Our thanks to the conference sponsors, whose support allows us to host
international speakers that are global leaders in their fields.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A
Table A1. Contributing speakers.
Speaker Affiliation
Prof. Valentina Cauda Politecnico di Torino, Italy
Center for Computational Imaging and Personalized Diagnostics, Case
Prof. Anant Madabhushi
Western Reserve University, USA
Trinity Translational Medicine Institute, Trinity College Dublin, St. James’s
Prof. Jacintha O’Sullivan
Hospital, Ireland
Dr. Eric Chevet French Institute of Health and Medical Research, University of Rennes, France
Dr. Anthony Letai Dana-Farber Cancer Institute, Harvard Medical School, USA
French Institute of Health and Medical Research, Institut Curie, PSL Research
Prof. Clotilde Thery
University, France
References
1. Hasin, Y.; Seldin, M.; Lusis, A. Multi-omics approaches to disease. Genome Biol. 2017, 18, 83. [CrossRef]
[PubMed]
2. Gillies, R.J.; Kinahan, P.E.; Hricak, H. Radiomics: Images Are More than Pictures, They Are Data. Radiology
2016, 278, 563–577. [CrossRef] [PubMed]
3. Saltz, J.; Almeida, J.; Gao, Y.; Sharma, A.; Bremer, E.; DiPrima, T.; Saltz, M.; Kalpathy-Cramer, J.; Kurc, T.
Towards Generation, Management, and Exploration of Combined Radiomics and Pathomics Datasets for
Cancer Research. AMIA Jt. Summits Transl. Sci. Proc. 2017, 2017, 85–94. [PubMed]
4. Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and
opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [CrossRef] [PubMed]
5. Yordanova, A.; Eppard, E.; Kürpig, S.; Bundschuh, R.A.; Schönberger, S.; Gonzalez-Carmona, M.;
Feldmann, G.; Ahmadzadehfar, H.; Essler, M. Theranostics in nuclear medicine practice. Onco Targets
Ther. 2017, 10, 4821–4828. [CrossRef] [PubMed]
6. Maas, S.L.N.; Breakefield, X.O.; Weaver, A.M. Extracellular vesicles: Unique intercellular delivery vehicles.
Trends Cell Biol. 2017, 27, 172–188. [CrossRef] [PubMed]
7. Montero, J.; Sarosiek, K.A.; DeAngelo, J.D.; Maertens, O.; Ryan, J.; Ercan, D.; Piao, H.; Horowitz, N.S.;
Berkowitz, R.S.; Matulonis, U.; et al. Drug-induced death signaling strategy rapidly predicts cancer response
to chemotherapy. Cell 2015, 160, 977–989. [CrossRef] [PubMed]
8. Wang, H.; Mu, X.; He, H.; Zhang, X.-D. Cancer Radiosensitizers. Trends Pharmacol. Sci. 2018, 39, 24–48.
[CrossRef] [PubMed]
9. Lim, E.K.; Kim, T.; Paik, S.; Haam, S.; Huh, Y.-M.; Lee, K. Nanomaterials for theranostics: Recent advances
and future challenges. Chem. Rev. 2015, 115, 327–394. [CrossRef] [PubMed]
10. Cauda, V.; Schlossbauer, A.; Kecht, J.; Zürner, A.; Bein, T. Multiple core-shell functionalized colloidal
mesoporous silica nanoparticles. J. Am. Chem. Soc. 2009, 131, 11361–11370. [CrossRef] [PubMed]
Cancers 2018, 10, 208 8 of 9
11. Argyo, C.; Cauda, V.; Engelke, H.; Rädler, J.; Bein, G.; Bein, T. Heparin-coated colloidal mesoporous silica
nanoparticles efficiently bind to antithrombin as an anticoagulant drug-delivery system. Chemistry 2012, 18,
428–432. [CrossRef] [PubMed]
12. Cauda, V.; Argyo, C.; Bein, T. Impact of different PEGylation patterns on the long-term bio-stability of
colloidal mesoporous silica nanoparticles. J. Mater. Chem. 2010, 20, 8693–8699. [CrossRef]
13. Mackowiak, S.A.; Schmidt, A.; Weiss, V.; Argyo, C.; von Schirnding, C.; Bein, T.; Bräuchle, C. Targeted drug
delivery in cancer cells with red-light photoactivated mesoporous silica nanoparticles. Nano Lett. 2013, 13,
2576–2583. [CrossRef] [PubMed]
14. Cauda, V.; Engelke, H.; Sauer, A.; Arcizet, D.; Bräuchle, C.; Rädler, J.; Bein, T. Colchicine-loaded lipid
bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell
uptake. Nano Lett. 2010, 10, 2484–2492. [CrossRef] [PubMed]
15. Schlossbauer, A.; Sauer, A.M.; Cauda, V.; Schmidt, A.; Engelke, H.; Rothbauer, U.; Zolghadr, K.; Leonhardt, H.;
Bräuchle, C.; Bein, T. Cascaded photoinduced drug delivery to cells from multifunctional core-shell
mesoporous silica. Adv. Healthc. Mater. 2012, 1, 316–320. [CrossRef] [PubMed]
16. Dumontel, B.; Canta, M.; Engelke, H.; Chiodoni, A.; Racca, L.; Ancona, A.; Limongi, T.; Canavese, G.;
Cauda, V. Enhanced biostability and cellular uptake of zinc oxide nanocrystals shielded with a phospholipid
bilayer. J. Mater. Chem. B 2017, 5, 8799–8813. [CrossRef] [PubMed]
17. Ancona, A.; Dumontel, B.; Garino, N.; Demarco, B.; Chatzitheodoridou, D.; Fazzini, W.; Engelke, H.; Cauda, V.
Lipid-Coated Zinc Oxide Nanoparticles as Innovative ROS-Generators for Photodynamic Therapy in Cancer
Cells. Nanomaterials 2018, 8, 143. [CrossRef] [PubMed]
18. Lee, G.; Sparks, R.; Ali, S.; Shih, N.N.C.; Feldman, M.D.; Spangler, E.; Rebbeck, T.; Tomaszewski, J.E.;
Madabhushi, A. Co-occurring gland angularity in localized subgraphs: Predicting biochemical recurrence in
intermediate-risk prostate cancer patients. PLoS ONE 2014, 9, e97954. [CrossRef] [PubMed]
19. Romo-Bucheli, D.; Janowczyk, A.; Gilmore, H.; Romero, E.; Madabhushi, A. Automated tubule nuclei
quantification and correlation with oncotype dx risk categories in ER+ breast cancer whole slide images.
Sci. Rep. 2016, 6, 32706. [CrossRef] [PubMed]
20. Lewis, J.S., Jr.; Ali, S.; Luo, J.; Thorstad, W.L.; Madabhushi, A. A quantitative histomorphometric classifier
(QuHbIC) identifies aggressive versus indolent p16-positive oropharyngeal squamous cell carcinoma. Am. J.
Surg. Pathol. 2014, 38, 128–137. [CrossRef] [PubMed]
21. Prasanna, P.; Tiwari, P.; Madabhushi, A. Co-occurrence of local anisotropic gradient orientations (CoLlAGe):
A new radiomics descriptor. Sci. Rep. 2016, 6, 37241. [CrossRef] [PubMed]
22. Lee, G.; Singanamalli, A.; Wang, H.; Feldman, M.; Master, S.; Shih, N.; Spangler, E.; Rebbeck, T.;
Tomaszewski, J.; Madabhushi, A. Supervised multi-view canonical correlation analysis (sMVCCA):
Integrating histologic and proteomic features for predicting recurrent prostate cancer. IEEE Trans. Med.
Imaging 2015, 34, 284–297. [CrossRef] [PubMed]
23. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria in cancer cells: What is so special about them?
Trends Cell Biol. 2008, 18, 165–173. [CrossRef] [PubMed]
24. Murphy, T.J.; Ravi, N.; Reynolds, J.V. Treatment options for esophageal cancer. Expert Opin. Pharmacother.
2008, 9, 3197–3210. [CrossRef] [PubMed]
25. Geh, J.I.; Crellin, A.M.; Glynne-Jones, R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal
cancer. Br. J. Surg. 2001, 88, 338–356. [CrossRef] [PubMed]
26. Lynam-Lennon, N.; Maher, S.G.; Maguire, A.; Phelan, J.; Muldoon, C.; Reynolds, J.V.; O’Sullivan, J. Altered
mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal
adenocarcinoma. PLoS ONE 2014, 9, e100738. [CrossRef] [PubMed]
27. Chircop, M.; Speidel, D. Cellular stress responses in cancer and cancer therapy. Front. Oncol. 2014, 4, 304.
[CrossRef] [PubMed]
28. Cubillos-Ruiz, J.R.; Bettigole, S.E.; Glimcher, L.H. Tumorigenic and immunosuppressive effects of
endoplasmic reticulum stress in cancer. Cell 2017, 168, 692–706. [CrossRef] [PubMed]
29. Obacz, J.; Avril, T.; Le Reste, P.J.; Urra, H.; Quillien, V.; Hetz, C.; Chevet, E. Endoplasmic reticulum proteostasis
in glioblastoma-From molecular mechanisms to therapeutic perspectives. Sci. Signal. 2017, 10, 2323.
[CrossRef] [PubMed]
Cancers 2018, 10, 208 9 of 9
30. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.;
Marosi, C.; Bogdahn, U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
31. Lhomond, S.; Avril, T.; Dejeans, N.; Voutetakis, K.; Doultsinos, D.; McMahon, M.; Pineau, R.; Obacz, J.;
Papadodima, O.; Jouan, F.; et al. Dual IRE1 RNase functions dictate glioblastoma development. EMBO Mol.
Med. 2018, 10, e7929. [CrossRef] [PubMed]
32. Vo, T.T.; Letai, A. BH3-only proteins and their effects on cancer. Adv. Exp. Med. Biol. 2010, 687, 49–63.
[PubMed]
33. Letai, A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 2017, 23, 1028–1035.
[CrossRef] [PubMed]
34. Ni Chonghaile, T.; Sarosiek, K.A.; Vo, T.T.; Ryan, J.A.; Tammareddi, A.; Moore Vdel, G.; Deng, J.;
Anderson, K.C.; Richardson, P.; Tai, Y.T.; et al. Pretreatment mitochondrial priming correlates with clinical
response to cytotoxic chemotherapy. Science 2011, 334, 1129–1133. [CrossRef] [PubMed]
35. Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J.P.; Primdal-Bengtson, B.; Dingli, F.; Loew, D.;
Tkach, M.; Théry, C. Proteomic comparison defines novel markers to characterize heterogeneous populations
of extracellular vesicle subtypes. Proc. Natl. Acad. Sci. USA 2016, 113, E968–E977. [CrossRef] [PubMed]
36. Tkach, M.; Kowal, J.; Zucchetti, A.E.; Enserink, L.; Jouve, M.; Lankar, D.; Saitakis, M.; Martin-Jaular, L.;
Théry, C. Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes.
EMBO J. 2017, 36, 3012–3028. [CrossRef] [PubMed]
37. Tkach, M.; Kowal, J.; Thery, C. Why the need and how to approach the functional diversity of extracellular
vesicles. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2018, 373, 1737. [CrossRef] [PubMed]
38. Wibmer, A.; Hricak, H.; Gondo, T.; Matsumoto, K.; Veeraraghavan, H.; Fehr, D.; Zheng, J.; Goldman, D.;
Moskowitz, C.; Fine, S.W.; et al. Haralick texture analysis of prostate MRI: Utility for differentiating
non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason
scores. Eur. Radiol. 2015, 25, 2840–2850. [CrossRef] [PubMed]
39. Modelska, A.; Quattrone, A.; Re, A. Molecular portraits: The evolution of the concept of transcriptome-based
cancer signatures. Brief. Bioinform. 2015, 16, 1000–1007. [CrossRef] [PubMed]
40. Gilligan, K.E.; Dwyer, R.M. Engineering Exosomes for Cancer Therapy. Int. J. Mol. Sci. 2017, 18, 1122.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).